Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN)’s stock price shot up 4.5% on Wednesday . The company traded as high as $2.34 and last traded at $2.34, 200 shares traded hands during trading. A decline of 99% from the average session volume of 29,043 shares. The stock had previously closed at $2.24.

Several research analysts have recently issued reports on the stock. HC Wainwright downgraded shares of Rexahn Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 7th. Zacks Investment Research upgraded shares of Rexahn Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $3.25 price objective for the company in a report on Saturday, August 10th. Ifs Securities cut Rexahn Pharmaceuticals from a “strong-buy” rating to a “market perform” rating in a research report on Wednesday, August 7th. Finally, ValuEngine upgraded Rexahn Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Three investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $40.75.

The stock has a fifty day simple moving average of $3.13. The company has a market capitalization of $9.33 million, a P/E ratio of -0.44 and a beta of 1.02. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.87 and a quick ratio of 4.87.

Rexahn Pharmaceuticals (NASDAQ:REXN) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.95) by $0.34. On average, equities research analysts forecast that Rexahn Pharmaceuticals, Inc. will post -2.26 EPS for the current fiscal year.

About Rexahn Pharmaceuticals (NASDAQ:REXN)

Rexahn Pharmaceuticals, Inc is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer.

Featured Story: Resistance Level

Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.